A citation-based method for searching scientific literature

Chantal Mathieu, Paresh Dandona, Pieter Gillard, Peter Senior, Christoph Hasslacher, Eiichi Araki, Marcus Lind, Stephen C Bain, Serge Jabbour, Niki Arya, Lars Hansen, Fredrik Thorén, Anna Maria Langkilde. Diabetes Care 2018
Times Cited: 120



Tadej Battelino, Thomas Danne, Richard M Bergenstal, Stephanie A Amiel, Roy Beck, Torben Biester, Emanuele Bosi, Bruce A Buckingham, William T Cefalu, Kelly L Close, Claudio Cobelli, Eyal Dassau, J Hans DeVries, Kim C Donaghue, Klemen Dovc, Francis J Doyle, Satish Garg, George Grunberger, Simon Heller, Lutz Heinemann, Irl B Hirsch, Roman Hovorka, Weiping Jia, Olga Kordonouri, Boris Kovatchev, Aaron Kowalski, Lori Laffel, Brian Levine, Alexander Mayorov, Chantal Mathieu, Helen R Murphy, Revital Nimri, Kirsten Nørgaard, Christopher G Parkin, Eric Renard, David Rodbard, Banshi Saboo, Desmond Schatz, Keaton Stoner, Tatsuiko Urakami, Stuart A Weinzimer, Moshe Phillip. Diabetes Care 2019
Times Cited: 689




List of shared articles



Times cited


Effect of short-term use of dapagliflozin on impaired awareness of hypoglycaemia in people with type 1 diabetes.
Lian A van Meijel, Cees J Tack, Bastiaan E de Galan. Diabetes Obes Metab 2021
0

Efficacy and Safety of SGLT2 Inhibitors in Type 1 Diabetes After the Introduction of an Off-Label Use Protocol for Clinical Practice.
Ane Bayona Cebada, Lía Nattero-Chávez, Sara Alonso Díaz, Héctor F Escobar-Morreale, Manuel Luque-Ramírez. Diabetes Technol Ther 2020
1

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes.
Marc Evans, Debbie Hicks, Dipesh Patel, Vinod Patel, Phil McEwan, Umesh Dashora. Diabetes Ther 2020
15

Sodium-glucose cotransporter 2 inhibitors improved time-in-range without increasing hypoglycemia in Japanese patients with type 1 diabetes: A retrospective, single-center, pilot study.
Daisuke Suzuki, Hodaka Yamada, Masashi Yoshida, Shunsuke Funazaki, Misato Amamoto, Jun Morimoto, Kazuo Hara. J Diabetes Investig 2020
5

Two clinical cases of adjunctive use of a SGLT-2 inhibitor in type 1 diabetes.
Thorsten Siegmund, Francisco Javier Ampudia-Blasco, Oliver Schnell. Diabetes Res Clin Pract 2020
2

Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme.
Jason Gordon, Thomas Danne, Lee Beresford-Hulme, Hayley Bennet, Amarjeet Tank, Christopher Edmonds, Fredrik Thorén, Markus Florian Scheerer, Phil McEwan. Diabetes Ther 2020
1

Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.
Chantal Mathieu, Gottfried Rudofsky, Moshe Phillip, Eiichi Araki, Marcus Lind, Niki Arya, Fredrik Thorén, Markus F Scheerer, Nayyar Iqbal, Paresh Dandona. Diabetes Obes Metab 2020
15